PremiumThe FlyPiper says SpringWorks deal suggests Immunome’s varegacestat ‘undervalued’ Immunome initiated with a Buy at Lake Street Biotech Alert: Searches spiking for these stocks today PremiumRatingsImmunome’s Promising Pipeline and Strategic Advancements Support Buy Rating Immunome’s 2024 Financial Results and Pipeline Progress Immunome price target lowered to $25 from $35 at Guggenheim PremiumThe FlyImmunome $125M Spot Secondary; price range $7.50-$8.00 Immunome announces $125M common stock offering Immunome CFO Relocation and Compensation Package Unveiled 
